CEO Paul Hastings describes his opinion of the benefits of an NK cell approach over T-cells, and discusses the work Nkarta has done to get to a high dose that should tell a clear story of the profile of this by year end. Coverage brought to you by

CEO Dannielle Appelhans describes how the platform works and how the company chose to focus on type 1 diabetes at this time. COUR also has partnerships with Takeda and Genentech. Coverage brought to you by

Founder & CEO Viswa Colluru describes the platform and how he believes it is differentiated from other AI discovery platforms Plus, discussing the lead program and why he believes there is ample room to meet unmet need in the large atopic dermatitis population even with big medicines on the market. Coverage brought to you by

President & CEO Marianne De Backer describes the unmet need in Hepatitis Delta and why she believes the dual antibody + siRNA is the right approach in this case. Plus, how investors thing about infectious disease vs oncology. Coverage brought to you by

CEO James Mackay describes the company's therapy, dotinurad, which has been approved in Japan since 2020. It is a URAT1 inhibitor, a mechanism that he and his team are very familiar with. Coverage brought to you by

COO Abhijit Bhatia describes how it works, and walks us through the design of the phase 3 and Rakuten Medical's global ambitions. Coverage brought to you by

Co-Founder and CEO Pierre Belichard describes the program, which is made up of four synthetic microbial-derived peptides designed to mimic CD20, CD22, CD37 and CD268, and UCP2, and walks us through the recent medical meeting presentations. Plus, Enterome's efforts to get investors or a strategic partner to support the phase 3. Coverage brought to you by

CEO Marcio Souza walks us through essential tremor and the mechanism of ulixacaltamide, and also comments on a recent seizure trial that did not succeed. Plus, preparing for potential commercial launches and how he thinks about M&A. Coverage brought to you by

CEO Nicholas Hertz describes this approach, which was recently made famous through the success of Karuna. Andrew Miller, a founder of Karuna, recently joined Montara's board. Coverage brought to you by

CEO Morten Graugaard discusses the limitations of previous generations of macrocycles and describes what he believes the power is behind the Orbis platform. Coverage brought to you by

The company's lead programs, which are both clinical target ROR1 x B7H3 and EGFT x MUC1. He describes how having two antigens can be beneficial especially in cases where one of the two targets is only modestly express, and he also discusses the difference between AND gating and OR gating. Coverage brought to you by

HAYA Co-Founder & CEO Samir Ounzain discusses the WISPER target that came out of the company's work of cataloging long non-coding RNAs, and the role that downregulating it might play in stopping the progression of nonobstructive hypertrophic cardiomyopathy. Plus, other programs, and where an understanding of the regulatory portion of the genome could ultimately take us. Coverage brought to you by

Co-Founder and CEO Serge Saxonov reflects on the progress of the last decade of the Human Cell Atlas Project, how 10x Genomics' tools have helped researchers along the way, and how Atera can take this kind of work to a whole new level. #sponsored

LB2501 is a CD19/CD20 dual targeting CAR-T. He discusses the EHA data, and next steps for the program. Plus, a review of last week's DLL3 data from ASCO and how he thinks about partnering and the competitive landscape.

With M&A news like GSK's $10.6B acquisition of Nuvalent and more positive clinical trial data in the pancreatic cancer space, biotech mostly outperformed the broader market this week.

CEO Richard Paulson walks us through the unmet need in myelofibrosis and the phase three data, which almost doubled the percent of patients achieving SVR35 (a measure of spleen volume reduction) at Week 24, one of the trial's co-primary endpoints. The company will also have a key pivotal trial readout in endometrial cancer sometime in the middle of this year.

He says he believes the Roche deal is an important transaction for the entire field of degraders. Plus, discussing antibody-degrader conjugates and an update on the company's immunology programs as well.

She shares a data update for both, which she believes are as strong as autologous CAR-T, and discusses recent FDA feedback Caribou has received from FDA on the pivotal trial design for the CD19 program in 2L LBCL.

From the Victoria House life sciences center in London, Co-Founders Alex Evans and Alberto Conti talk about winning the golden ticket and how it has already been helping them, and share advice for others who might be interested in applying one day. Plus, general advice for new bio entrepreneurs.

Inspired by the Nobel Prize winning work of Carolyn Bertozzi, Co-Founder and CEO Sophie James describes the science that underlies the company. Plus, moving into Victoria House in London and her advice for other entrepreneurs.